These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 17631347

  • 1. Pathological features after radical prostatectomy in potential candidates for active monitoring.
    Griffin CR, Yu X, Loeb S, Desireddi VN, Han M, Graif T, Catalona WJ.
    J Urol; 2007 Sep; 178(3 Pt 1):860-3; discussion 863. PubMed ID: 17631347
    [Abstract] [Full Text] [Related]

  • 2. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M, Stamey TA, McNeal JE, Yemoto CM.
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome.
    Pinthus JH, Witkos M, Fleshner NE, Sweet J, Evans A, Jewett MA, Krahn M, Alibhai S, Trachtenberg J.
    J Urol; 2006 Sep; 176(3):979-84; discussion 984. PubMed ID: 16890675
    [Abstract] [Full Text] [Related]

  • 5. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
    Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, Catalona WJ.
    J Urol; 2007 Jan; 177(1):102-6; discussion 106. PubMed ID: 17162013
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.
    Boccon-Gibod LM, Dumonceau O, Toublanc M, Ravery V, Boccon-Gibod LA.
    Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298
    [Abstract] [Full Text] [Related]

  • 8. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L, Poulos CK, Pan CX, Jones TD, Daggy JK, Eble JN, Koch MO.
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [Abstract] [Full Text] [Related]

  • 9. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
    Suekane S, Noguchi M, Nakashima O, Yamada S, Kojiro M, Matsuoka K.
    Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
    [Abstract] [Full Text] [Related]

  • 10. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    Ploussard G, Salomon L, Xylinas E, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A.
    J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
    [Abstract] [Full Text] [Related]

  • 11. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
    Thong AE, Shikanov S, Katz MH, Gofrit ON, Eggener S, Zagaja GP, Shalhav AL, Zorn KC.
    J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.
    Loeb S, Roehl KA, Thaxton CS, Catalona WJ.
    Urology; 2008 Jul; 72(1):143-7. PubMed ID: 18436287
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
    Loeb S, Sutherland DE, D'Amico AV, Roehl KA, Catalona WJ.
    Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
    [Abstract] [Full Text] [Related]

  • 16. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F.
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
    Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, Babaian RJ.
    J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
    [Abstract] [Full Text] [Related]

  • 19. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer.
    Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC, Terris MK, SEARCH Database Study Group.
    J Urol; 2006 Apr; 175(4):1298-302; discussion 1302-3. PubMed ID: 16515984
    [Abstract] [Full Text] [Related]

  • 20. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV, Humphreys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI, Freedland SJ.
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.